SMAD2 and neoplasm: Our findings support a model in which KIT stimulates TGFβ expression to promote stroma formation and activation—resulting in CRC progression [36]—while simultaneously protecting the tumor cells against TGFβ-induced growth inhibition through suppression of SMAD2.